ABBV vs LLY: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Eli Lilly and Company · Healthcare
$939.47
+71.1% upside to fair value
High Conviction
Grade A
QuantHub Verdict
LLY has more upside to fair value
(+71.1%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
LLY |
| Current Price |
$208.05 |
$939.47 |
| Fair Value Estimate |
$217.50 |
$1,607.00 |
| Upside to Fair Value |
+4.5%
|
+71.1%
|
| Market Cap |
$367.9B |
$887.6B |
| Forward P/E |
14.9x
|
27.4x
|
| EV / EBITDA |
16.7x
|
35.8x
|
| Price / Sales |
6.1x
|
14.8x
|
| Price / FCF |
20.9x
|
107.6x
|
| Revenue Growth YoY |
+8.6%
|
+44.7%
|
| Gross Margin |
83.7%
|
83.8%
|
| Operating Margin |
34.7%
|
45.6%
|
| Return on Equity |
-129.24%
|
77.8%
|
| Dividend Yield |
3.2% |
0.56% |
| FCF Yield |
4.78%
|
0.93%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B. The company guided $80-83B for 2026, well above prior Street consensus, and launched Foundayo (oral GLP-1, FDA approved April 2026) with $1.5B pre-built inventory. At $939 the stock trades at 14.8x P/S, right at its 5-year median, and 27.4x for…
Accumulation Zones
| Metric |
ABBV |
LLY |
| Zone Low |
$163.13 |
$1,205.00 |
| Zone High |
$184.88 |
$1,366.00 |
| In Buy Zone? |
No
|
Yes
|